FDA Approves Rezenopy Nasal Spray for the Emergency Treatment of Opioid Overdose
The FDA has approved Rezenopy (naloxone hydrochloride) nasal spray 10mg for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. Rezenopy is manufactured by Summit Biosciences Inc.
- Rezenopy is a high dose naloxone hydrochloride nasal spray formulation containing 10mg of naloxone per spray available on prescription. Rezenopy nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
- Naloxone hydrochloride is an opioid antagonist that works to reverse the effects of opioids during an overdose, including respiratory depression, sedation, and hypotension.
- Common adverse reactions reported with Rezenopy include upper abdominal pain, nasopharyngitis and dysgeusia.
Source: FDA
